Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
A total of 167 human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily). At day 14, 87% of the fluconazole-treated patients were clinically cured, as opposed to 52% in the nystatin-treated group (P < .001). Fluconazole eradicated Candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (P < .001). The fluconazole group had fewer relapses noted on day 28 (18%, vs. 44% in the nystatin group; P < .001). This relapse difference no longer existed by day 42. Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.
Pons
V
V
Division of Infectious Disease, University of California Hospital, San Francisco 94143, USA.
Greenspan
D
D
Lozada-Nur
F
F
McPhail
L
L
Gallant
J E
JE
Tunkel
A
A
Johnson
C C
CC
McCarty
J
J
Panzer
H
H
Levenstein
M
M
Barranco
A
A
Green
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D009761:Nystatin / Q000627:therapeutic use*; D010608:Pharyngeal Diseases / Q000188:drug therapy*; D013535:Suspensions
D000935:Antifungal Agents; D013535:Suspensions; D009761:Nystatin; D015725:Fluconazole